Babafig 🇷🇪

Candidiasis Therapeutics Market Opportunities Across Oral, Topical and Intravenous Therapies

5 dk okuma
0
Yorumlar
48
Görüntülenme

According to Straits Research , the global candidiasis therapeutics market size was valued at USD 2.90 billion in 2025 and is projected to grow from USD 3.01 billion in 2026 to USD 4.07 billion by 2034, recording a CAGR of 3.83% during the forecast period (2026–2034). North America held the largest market share of 32.86% in 2025, while Asia Pacific is set to record the fastest growth at a CAGR of 5.83%.

  • Market Size 2025: USD 2.90 Billion

  • Market Size 2026: USD 3.01 Billion

  • CAGR (Forecast Period): 3.83%

  • Forecast Year: 2034

  • Projected Market Size: USD 4.07 Billion

  • Dominant Region: North America

  • Fastest Growing Region: Asia Pacific

Market Overview

Candidiasis therapeutics include medicines used to treat fungal infections caused by Candida species. These infections can affect the mouth, skin, genital area, bloodstream, and internal organs. Treatment options include azoles, polyenes, echinocandins, and other antifungal medicines administered through oral, intravenous, or topical routes. Hospitals, retail pharmacies, and online pharmacies provide access to these treatments, with the choice of medicine shaped by infection type, severity, and patient condition.

Growth Drivers

The incidence of recurrent fungal infections and invasive candidiasis supports the use of antifungal medicines across hospital and outpatient settings. Patients with weakened immune systems and those who receive intensive medical care often require specialized treatment for serious Candida infections. The availability of established drug classes such as azoles and echinocandins also supports treatment across different infection sites and clinical conditions.

Market Challenges

Drug interactions can complicate antifungal treatment, particularly among patients who take multiple medicines for underlying health conditions. Resistance among certain Candida species can also reduce the effectiveness of established therapies and make treatment selection more difficult. These issues may require additional diagnostic tests, specialist care, and alternative medicines, which can increase treatment costs.

Market Opportunities

Novel antifungal medicines offer pharmaceutical companies an opportunity to serve hospitals that treat patients with invasive or drug-resistant Candida infections. Developers can generate revenue through prescription therapies with new mechanisms of action and formulations for specific infection sites. Diagnostic companies can also work with hospitals and laboratories to link Candida identification with suitable treatment selection, creating opportunities through test sales and laboratory service contracts.

Segment Analysis

By drug class, azoles held a market share of 43.8% in 2025, supported by their widespread use across several forms of candidiasis and availability in different formulations. Echinocandins are set to record a CAGR of 5.15%, supported by the need for effective treatment of invasive Candida infections.

By infection type, vulvovaginal candidiasis held a share of 32.5% in 2025 due to its frequency and the availability of oral and topical antifungal treatments. Invasive candidiasis is set to record a CAGR of 5.15%, as healthcare providers require effective medicines for serious infections that affect the bloodstream and internal organs.

By route of administration, oral medicines held a market share of 45.5% in 2025 due to their convenience and use across several forms of candidiasis. Intravenous treatments are set to record a CAGR of 4.75%, supported by the need for systemic therapy among hospitalized patients with severe or invasive infections.

By distribution channel, drug stores and retail pharmacies held a share of 45.8% in 2025, supported by their role in the sale of medicines for common candidiasis infections. Online pharmacies are set to record a CAGR of 6.25%, as remote ordering and prescription refill services improve access to antifungal medicines.

Regional Analysis

North America held the largest share of the candidiasis therapeutics market in 2025, accounting for 32.86% of global revenue. Established healthcare systems, access to antifungal medicines, and surveillance of invasive fungal infections support the region's position. Asia Pacific is set to record the fastest growth at a CAGR of 5.83%, supported by wider access to diagnostic services, hospital-based treatment, and clinical guidance for Candida infections.

Competitive Landscape

The candidiasis therapeutics market is highly fragmented, with pharmaceutical companies and specialized antifungal drug developers competing through drug efficacy, product portfolios, and research into resistant infections. Key players include Pfizer Inc., Merck & Co., Inc., Astellas Pharma Inc., Gilead Sciences, Inc., and Bayer AG. Other participants include Teva Pharmaceutical Industries, Novartis, Sun Pharmaceutical Industries, Cipla, and Dr. Reddy's Laboratories. Companies focus on new antifungal mechanisms, improved formulations, and treatment options for difficult-to-treat infections.

Recent Developments

  • October 2026: CorMedix announced that the US Food and Drug Administration accepted a supplemental application for priority review of REZZAYO (rezafungin). The application seeks approval for prevention of invasive fungal infections in high-risk patients who undergo allogeneic hematopoietic stem cell transplantation.

  • April 2026: ISHA Therapeutics received US FDA Qualified Infectious Disease Product designation for ISHA-004, an investigational oral thin-film antifungal formulation for oropharyngeal candidiasis. The formulation is designed to adhere to oral and throat surfaces and deliver the antifungal agent directly to the infection site.

  • February 2026: SCYNEXIS announced that the first participants had received doses in a Phase 1 trial of intravenous SCY-247. The investigational antifungal is being developed for invasive candidiasis and prevention of invasive fungal infections.

Click to Read the Complete Insights & Report:  https://straitsresearch.com/report/candidiasis-therapeutics-market

Future Outlook

The candidiasis therapeutics market is expected to benefit from continued need for antifungal treatment and research into drug-resistant infections. New drug candidates and targeted formulations may broaden treatment options for patients with severe or recurrent candidiasis. Diagnostic partnerships and improved access to online pharmacies can also support treatment selection and distribution across healthcare settings.

About Straits Research

Straits Research is a market intelligence company that provides global business information and consulting services. The company offers market reports, industry analysis, and strategic insights to help organizations understand market trends, assess opportunities, and make informed business decisions.

Sponsorlu